{
  "schemaVersion": 1,
  "id": "research-157",
  "slug": "157-what-a-noninvasive-liver-score-measured-in-the-samara-trial",
  "title": "What a noninvasive liver score measured in the SAMARA trial",
  "catalogLabel": "GLP-1 SEMA",
  "productCollection": "https://heritagebiolabs.com/research-library/products/glp-1-sema",
  "productHandles": [
    "glp-1-sema-687",
    "glp-1-sema-688"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/glp-1-sema-687",
    "https://heritagebiolabs.com/product/glp-1-sema-688"
  ],
  "readingFocus": "Methods & identity",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 393,
  "sourceYears": [
    2026
  ],
  "paragraphs": [
    "Peptides are short chains of amino acids connected by peptide bonds. Some act as signals or activate receptors that help the body regulate nutrients. Semaglutide is a modified peptide that activates the GLP-1 receptor. The SAMARA study, published in 2026, asked whether noninvasive tests could detect a change in adults with suspected at-risk metabolic dysfunction-associated steatohepatitis, or MASH, who were assigned to semaglutide or placebo. [1]",
    "MASH is a form of metabolic liver disease involving fat buildup, inflammation and liver cell injury. Fibrosis means scarring. A biopsy can show these features in a small piece of liver tissue, but investigators also study measures that use scans and blood tests. The SAMARA team used these measures to identify adults likely to have at-risk disease. The main outcome was the change in the FibroScan-AST score, known as FAST, after 52 weeks. The score combines scan information with the level of an enzyme measured in the blood. [1]",
    "The study randomized 55 adults. Average FAST scores fell by 0.28 with semaglutide and 0.12 with placebo. The investigators also assessed body weight and other measures, including an MRI-based estimate of liver fat. These measures offer different information. A score that responds over time can help evaluate change in a study, while a liver tissue sample allows researchers to assess scarring and inflammation more directly. This particular trial addressed what happened to noninvasive measurements under its selection and follow-up procedures. [1]",
    "In the United States, the Wegovy injection label includes accelerated approval for adults with noncirrhotic MASH and moderate to advanced fibrosis, corresponding to stages F2 through F3. The indication rests on evidence of improvement in MASH and fibrosis under the conditions described by FDA. Accelerated approval allows the specified use while further evidence is gathered to confirm clinical benefit. The label separates the injection indication from those of the tablets. [2]",
    "SAMARA helps researchers judge whether a noninvasive score is responsive in a controlled experiment. The drop in FAST is a measurable trial outcome. It cannot by itself identify how an individual’s scarring changed or establish effects on later outcomes such as progression to cirrhosis. The trial’s main result and the labeled indication both concern MASH, but they answer different questions. Keeping the measure, formulation and studied population in view makes it possible to use each piece of evidence for the question it can address. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Veeral Ajmera et al. Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA). Alimentary Pharmacology & Therapeutics (publication 2026-01-12).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41527269/"
    },
    {
      "number": 2,
      "citation": "U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Drugs@FDA (publication 2026-06).",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218316s007lbl.pdf"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/157-what-a-noninvasive-liver-score-measured-in-the-samara-trial",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/157-what-a-noninvasive-liver-score-measured-in-the-samara-trial.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/157-what-a-noninvasive-liver-score-measured-in-the-samara-trial.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 032 - GLP-1 SEMA and GLP-2 TIRZ.docx",
    "sourceArticleNumber": 157,
    "contentSha256": "4ed7a736314a7fc217851f3cede236a40bade45df588183719a039c4b0758af8",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
